# Anti-CD25 Monoclonal Antibody for Prevention of Acute GVHD After Haploidentical HSCT

> **NCT07689630** · PHASE3 · RECRUITING · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 186 (estimated)

## Conditions studied

- Graft Versus Host Disease
- Hematologic Neoplasms

## Interventions

- **DRUG:** Methotrexate
- **BIOLOGICAL:** Anti-CD25 Monoclonal Antibody

## Key facts

- **NCT ID:** NCT07689630
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2028-05
- **Final completion:** 2028-05
- **Target enrollment:** 186 (ESTIMATED)
- **Last updated:** 2026-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07689630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07689630, "Anti-CD25 Monoclonal Antibody for Prevention of Acute GVHD After Haploidentical HSCT". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07689630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*